色瑞替尼(450 mg/d或600 mg/d随餐)对比750 mg/d空腹治疗ALK阳性非小细胞肺癌患者的疗效与安全性:ASCEND-8研究主要疗效结果
ASCEND-8是一项开放标签、I期、三臂研究,纳入初治和经治的晚期/转移性ALK阳性NSCLC患者。主要疗效分析显示,色瑞替尼450 mg随餐组、600 mg随餐组和750 mg空腹组的BIRC评估ORR分别为78.1%、72.5%和75.7%,中位缓解持续时间分别为不可评估、20.7个月和15.4个月。安全性分析显示450 mg随餐组的中位相对剂量强度最高、剂量减少和胃肠道毒性比例最低。
要点
- 色瑞替尼450 mg随餐对比750 mg空腹显示出 consistent 疗效和更少的胃肠道毒性。
- 450 mg随餐组BIRC评估ORR为78.1%,600 mg随餐组为72.5%,750 mg空腹组为75.7%。
- 450 mg随餐组中位相对剂量强度为100%,高于600 mg组78.5%和750 mg组83.7%。
核心结论
- 色瑞替尼450 mg随餐对比750 mg空腹显示出 consistent 疗效和更少的胃肠道毒性。
研究设计与样本
- ASCEND-8是一项开放标签、I期、三臂研究,纳入初治和经治的晚期/转移性NSCLC患者。
- 共306例患者随机分配至色瑞替尼450 mg随餐组(n=108)、600 mg随餐组(n=87)或750 mg空腹组(n=111)。
- 安全性分析纳入304例患者,疗效分析纳入198例初治患者(免疫组化证实ALK阳性),其中450 mg随餐组n=73、600 mg随餐组n=51、750 mg空腹组n=74。
主要发现
- BIRC评估的ORR在450 mg随餐组为78.1%(95%CI:66.9-86.9),600 mg随餐组为72.5%(95%CI:58.3-84.1),750 mg空腹组为75.7%(95%CI:64.3-84.9)。
- BIRC评估的中位缓解持续时间在450 mg随餐组为不可评估(95%CI:11.2-不可评估),600 mg随餐组为20.7个月(95%CI:15.8-不可评估),750 mg空腹组为15.4个月(95%CI:8.3-不可评估)。
- 安全性分析(n=304)显示,450 mg随餐组的中位相对剂量强度为100%,600 mg随餐组为78.5%,750 mg空腹组为83.7%。
- 450 mg随餐组剂量减少的患者比例为24.1%,600 mg随餐组为65.1%,750 mg空腹组为60.9%。
- 450 mg随餐组发生胃肠道毒性的患者比例为75.9%,600 mg随餐组为82.6%,750 mg空腹组为91.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In an earlier report of the ASCEND-8 study (open-label, phase I, three-arm study, treatment-naive patients and pre-treated patients with advanced/metastatic NSCLC), it was shown that ceritinib 450 mg with food had comparable exposure and better gastrointestinal tolerability than 750-mg fasted. METHODS: Here, we report efficacy and updated safety data from primary efficacy analysis of the ASCEND-8 study. Key secondary endpoints were overall response rate and duration of response, assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors 1.1. RESULTS: In total, 306 patients were randomized to ceritinib 450-mg fed (n = 108) or 600-mg fed (n = 87) or 750-mg fasted (n = 111), of which 304 patients were included in safety analysis and 198 treatment-naive patients (ALK receptor tyrosine kinase [ALK]-positive by immunohistochemistry) were included in the efficacy analysis (450-mg fed [n = 73], 600-mg fed [n = 51], and 750-mg fasted [n = 74]). The BIRC-assessed overall response rate was 78.1% (95% confidence interval [CI]: 66.9-86.9), 72.5% (95% CI: 58.3-84.1), and 75.7% (95% CI: 64.3-84.9), respectively; and the median duration of response (months) by BIRC was not estimable (NE) (95% CI: 11.2-NE), 20.7 (95% CI: 15.8-NE), and 15.4 (95% CI: 8.3-NE), respectively. Based on the safety analysis (n = 304), the 450-mg fed arm showed the highest median relative dose intensity (100% versus 78.5% versus 83.7%), lowest proportion of patients with dose reductions (24.1% versus 65.1% versus 60.9%), and lowest proportion of patients with gastrointestinal toxicities (75.9% versus 82.6% versus 91.8%). CONCLUSION: Ceritinib at a dose of 450 mg with food compared to 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity.
引用
- Cho BC, Obermannova R, Bearz A, et al. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. J Thorac Oncol. 2019. PMID: 30851442. doi:10.1016/j.jtho.2019.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。